The role of peptide YY in integrative gut physiology and potential role in obesity

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 1, 2007, Pages 52-57

  Grudell, April B M ^a   Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

Gastrointestinal peptide; Ileal brake; Obesity; Peptide YY; PYY

Indexed keywords

PEPTIDE YY; PEPTIDE YY[3-36]; UNCLASSIFIED DRUG;

APPETITE; BARIATRIC SURGERY; BRAIN REGION; BRAIN STEM; CALORIC INTAKE; CALORIC RESTRICTION; COLON; DIET RESTRICTION; DOSE RESPONSE; DRUG SAFETY; FOOD INTAKE; HUMAN; HYPOTHALAMUS; ILEUM; INTESTINE FUNCTION; NONHUMAN; OBESITY; PHYSIOLOGY; POSTPRANDIAL STATE; PROTEIN FUNCTION; REVIEW; VAGUS NERVE; WEIGHT REDUCTION;

ANIMALS; EATING; HUMANS; HUNGER; INTESTINES; OBESITY; PEPTIDE YY; SATIETY RESPONSE;

EID: 33847733119     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3280123119     Document Type: Review

References (64)

1. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285:417-418.
2. Tatemoto K, Nakano I, Makk G, et al. Isolation and primary structure of human peptide YY. Biochem Biophys Res Commun 1988; 157:713-717.
3. Grandt D, Teyssen S, Schimiczek M, et al. Novel generation of hormone receptor specificity by amino terminal processing of peptide YY. Biochem Biophys Res Commun 1992; 186:1299-1306.
4. Keire DA, Mannon P, Kobayashi M, et al. Primary structures of PYY, [Pro34]-PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 2000; 279:G126-G131.
5. Huda MSB, Wilding JPH, Pinkney JH. Gut peptides and the regulation of appetite. Obes Rev 2006; 7:163-182. This study gives a comprehensive but concise review of the major gastrointestinal peptides involved in appetite.
6. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): part 1 - distribution, release, and actions. Obes Surg 2006; 16:651-658. An excellent review of PYY and its various effects.
7. Fu-Cheng X, Anini Y, Chariot J, et al. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflugers Arch 1997; 433:571-579.
8. Adrian TE, Bacarese-Hamilton AJ, Allen JM, et al. Distribution of PYY in porcine and human gastrointestinal tract [abstract]. Regul Pept 1982; 4:355.
9. Ferri GL, Adrian TE, Allen JM, et al. Intramural distribution of regulatory peptides in the sigmoid-recto-anal region of the human gut. Gut 1988; 80:487-491.
10. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY (3-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
11. Broberger C. Brain regulation of food intake and appetite: molecules and networks. J Intern Med 2005; 258:301-327.
12. McGowan BMC, Bloom SR. Peptide YY and appetite control. Curr Opin Pharmacol 2004; 4:583-588.
13. Spiller RC, Trotman IF, Higgins BE, et al. The ileal brake: inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984; 26:365-374.
14. Read NW, McFarlane A, Kinsman RI, et al. Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Gastroenterology 1984; 86:274-280.
15. Hammer J, Lang K, Kletter K. Accelerated right colonic emptying after simulated upper gut hemorrhage. Am J Gastroenterol 1998; 93:628-631.
16. Taylor IL. Role of peptide YY in endocrine control of digestion. J Dairy Sci 1993; 76:2094-2101.
17. Van Citters GW, Lin HC. The ileal brake: a fifteen-year progress report. Curr Gastroenterol Rep 1999; 1:404-409.
18. Lin HC, Chen JH. Slowing of intestinal transit by fat depends on an ondansetron-sensitive, efferent serotonergic pathway. Neurogastroenterol Motil 2003; 15:317-322.
19. Martin MT, Azpiroz F, Malagelada J-R. Melatonin as a modulator of the ileal brake mechanism. Scand J Gastroenterol 2005; 40:559-563.
20. Pellissier S, Sasaki K, Le-Nguyen D, et al. Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine. Neurogastroenterol Motil 2004; 16:455-463.
21. Lin HC, Zhao XT, Wang L, et al. Fat-induced ileal brake in the dog depends on peptide YY. Gastroenterology 1996; 110:1491-1495.
22. Clark TJ, Sahu A, Kalra PS, et al. Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY. Regul Pept 1987; 17:31-39.
23. Stanley BG, Daniel DR, Chin AS, et al. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 1985; 6:1205-1211.
24. Corp ES, McQuade J, Krasnicki S, et al. Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides 2001; 22:493-499.
25. Deng X, Guarita DR, Pedroso MR, et al. PYY inhibits CCK-stimulated pancreatic secretion through the area postrema in unanesthetized rats. Am J Physiol Regul Integr Comp Physiol 2001; 281:R645-R653.
26. Chen X, DiMaggio DA, Han SP, et al. Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors. Am J Physiol 1997; 273:H1737-H1744.
27. Savage AP, Adrian TE, Carolan G, et al. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28:166-170.
28. Pappas TN, Debas HT, Taylor IL. Enterogastrone-like effect of peptide YY is vagally mediated in the dog. J Clin Invest 1986; 77:49-53.
29. Putnam WS, Liddle RA, Williams JA. Inhibitory regulation of rat exocrine pancreas by peptide YY and pancreatic polypeptide. Am J Physiol 1989; 256:G698-G703.
30. Keller J, Holst JJ, Layer P. Inhibition of human pancreatic and biliary output but not intestinal motility by physiological intraileal lipid loads. Am J Physiol Gastrointest Liver Physiol 2006; 290:704-709.
31. Koda S, Date Y, Murakami N, et al. The role of the vagal nerve in peripheral PYY 3-36-induced feeding reduction in rats. Endocrinology 2005; 146:2369-2375.
32. Abbott CR, Monteiro M, Small CJ, et al. The inhibitory effects of peripheral administration of peptide YY 3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005; 1044:127-131.
33. Halatchev IG, Cone RD. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 2005; 1:159-168.
34. Pittner RA, Moore CX, Bhavsar SP, et al. Effects of PYY[3-36] in rodent models for diabetes and obesity. Int J Obes Relat Metab Disord 2004; 28:963-971.
35. Boggiano MM, Chandler PC, Oswald KD, et al. PYY3-36 as an antiobesity drug target. Obes Rev 2005; 6:307-322. Excellent review of PYY rodent studies that critically examines the potential for PYY to become an antiobesity drug.
36. Halatchev IG, Ellacott KL, Fan W, et al. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 2004; 145:2585-2590.
37. Challis BG, Pinnock SB, Coll AP, et al. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 2003; 311:915-919.
38. Martin NM, Small CJ, Sajedi A, et al. Preobese and obese agouti mice are sensitive to the anorectic effects of peptide YY (3-36) but resistant to ghrelin. Int J Obes Relat Metab Disord 2004; 28:886-893.
39. Challis BG, Coll AP, Yeo GS, et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY (3-36). Proc Natl Acad Sci U S A 2004; 101:4695-4700.
40. Sainsbury A, Schwarzer C, Couzens M, et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. PNAS 2002; 99:8938-8943.
41. Conarello SL, Li Z, Ronan J, et al. Mice lacking depeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A 2003; 100:6825-6830.
42. Pappas TN, Debas HT, Taylor IL. Peptide YY: metabolism and effect on pancreatic secretion in dogs. Gastroenterology 1985; 89:1387-1392.
43. Perez-Tilve D, Nogueiras R, Mallo F, et al. Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance and metabolism. Endocrine 2006; 29:61-71.
44. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89:1070-1077.
45. Lin HC, Chey WY. Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs. Regul Pept 2003; 114:131-135.
46. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
47. Kim B-J, Carlson OD, Jang H-J, et al. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005; 90:6665-6671. This study provides a concise review of PYY and the difference in its postprandial levels between men and women.
48. Stock S, Leichner P, Wong AC, et al. Ghrelin, PYY, GIP and hunger responses to a mixed meal in anorexic, obese and control female adolescents. J Clin Endocrinol Metab 2005; 90:2161-2168.
49. Vazquez Roque MI, Camilleri M, Stephens DA, et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight and obese people. Gastroenterology (in press).
50. Roth CL, Enriori PJ, Harz K, et al. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 2005; 90:6386-6391.
51. Le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147:3-8.
52. Park MI, Camilleri M. Gastric motor and sensory functions in obesity. Obes Res 2005; 13:491-500.
53. Sileno AP, Brandt GC, Spann BM, et al. Lower mean weight after 14 days intravenous administration peptide YY3-36 in rabbits. International Journal of Obesity 2006; 30:68-72.
54. Kampe J, Pfluger P, Castaneda TR, et al. Influence of acute and chronic changes in energy balance on circulating concentrations of human peptide YY [abstract]. Keystone Obesity Meeting 2005.
55. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): part II - changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006; 16:795-803. This is an excellent review of the changes in PYY levels after a variety of gastrointestinal weight-loss surgical procedures.
56. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002; 12:324-327.
57. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90:359-365.
58. Morinigo R, Moize V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006; 91:1735-1740.
59. Ockander L, Hedenbro JL, Rehfeld JF, et al. Jejunoileal bypass changes the duodenal cholecystokinin and somatostatin cell density. Obes Surg 2003; 13:584-590.
60. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2006; 129:1430-1436.
61. Chelikani PK, Haver AC, Reeve JR, et al. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 2006; 290:R298-R305.
62. Moran TH, Smedh U, Kinzig KP, et al. Peptide YY (3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol 2004; 288:R384-R388.
63. Nastech Pharmaceutical Company I. Nastech announces positive phase 1-c clinical results of PYY3-36 nasal spray for obesity 2004. http://investor. nasTechnicalcom/phoenix.zhtml?c=83674&p.=irol-newsArticle&ID= 586170&highlight=.
64. Park A, Sileno A, Brandt G, et al. Nasal peptide YY 3-36: phase 1 dose-ranging and safety study in healthy subjects [abstract]. 13th European Congress on Obesity 2004.